Ocedurenone - Novo Nordisk
Alternative Names: KBP-5074; NN-6023Latest Information Update: 02 Jul 2024
At a glance
- Originator KBP Biosciences
- Class Antihypertensives; Small molecules
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal hypertension
Most Recent Events
- 26 Jun 2024 KBP Biosciences terminates the phase III Clarion-CKD trial in Renal hypertension in US, Canada, Georgia, Hong Kong, Hungary, South korea, Spain, Taiwan, South Africa, Serbia, Poland, Malaysia, Lithuania, Latvia, Israel, Germany, Czech Republic, Croatia, China, Bosnia-Herzegovina, Australia due to not meeting its primary endpoint (NCT04968184)
- 16 Oct 2023 Novo Nordisk acquires ocedurenone from KBP Biosciences
- 07 Sep 2023 Pharmacokinetics and adverse events data from a phase I trial in Renal-hypertension (In volunteers) presented at theHypertension Scientific Session 2023(HTN-2023)